

Menopause

The Journal of The North American Menopause Society

VOLUME 28, ISSUE 1 2021

SDC

Supplemental Digital Content is available.

OPEN

Open Access article.

Contents

Editorials

Surgical menopause: health implications and hormonal management Andrew M. Kaunitz, MD, FACOG, NCMP, and Stephanie Faubion, MD, FACP, NCMP

4

Clinically undiagnosed vertebral fractures: why and how to approach when we do not know they exist?

Deborah M. Kado, MD, MS

6

Early menarche and worse cardiovascular health: an emerging risk factor? Ewa M. Gross-Sawicka, MD, PhD, and Eiran Z. Gorodeski, MD, MPH

Original Studies

Unnecessary bilateral salpingo-oophorectomy at the time of hysterectomy and potential for ovarian preservation

Jellena Wong, MD, Ally Murji, MD, MPH, Zahra Sunderji, MD, Ovina Chow, BScH, Jodi Shapiro, MD, MHSc, Wendy Wolfman, MD, and Lindsay Shirreff, MD, MSc(HQ) Concurrent bilateral salpingo-oophorectomy performed by generalists and at community hospitals were less likely to have preoperative indications. Ovarian preservation was potentially possible for 8%.

12

Prevalence and risk factors of morphometric vertebral fracture in apparently healthy osteopenic postmenopausal Thai women

Lalita Wattanachanya, MD, and Chatlert Pongchaiyakul, MD Morphologic vertebral fracture was common in apparently healthy postmenopausal women with osteopenia. Advancing age and higher FRAX scores were associated with higher prevalence of morphometric vertebral fracture.

(continued)



18

Age at menarche and cardiovascular health: results from the NHANES 1999-2016

Yi Zheng, MPH, Tony S. Wen, MD, Yun Shen, MPH, and Hui Hu, PhD

Early menarche is associated with worse cardiovascular health among women, especially among those aged 25-44 years. Age at menarche may play an important role in maintaining and improving cardiovascular health among women.

25

Hypertensive disorders of pregnancy and menopausal symptoms: a cross-sectional study from the data registry on experiences of aging, menopause, and sexuality

Stephanie S. Faubion, MD, MBA, Amanda King, MD, Andrea G. Kattah, MD, Carol L. Kuhle, DO, MPH, Richa Sood, MD, MS, Juliana M. Kling, MD, MPH, Kristin C. Mara, MS, and Ekta Kapoor, MBBS

In this large cross-sectional study, a history of hypertensive disorders of pregnancy was associated with more bothersome menopausal symptoms, a finding which requires additional study to determine the strength of this association, underlying mechanisms of the association, and clinical implications for cardiovascular risk prediction in women.

OPEN

32

Effects of combined 17β -estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial

Denise R. Black, MD, FRCSC, Mary Jane Minkin, MD, Shelli Graham, PhD, Brian Bernick, MD, and Sebastian Mirkin, MD

Data from the randomized, placebo-controlled, phase 3 REPLENISH trial revealed no overall clinically significant changes in body weight and sitting blood pressure in all groups, showing no impact of TX-001HR on these cardiovascular disease risk factors. Together with previously reported efficacy and safety data, the results of this analysis on weight and blood pressure add to the efficacy and safety profile for the approved 1 mg/100 mg E2/P4 dose, which is an option for postmenopausal women with a uterus and moderate to severe vasomotor symptoms.

SDC

40

Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial

Jay Jay Thaung Zaw, MBBS, Peter R.C. Howe, PhD, and Rachel H.X. Wong, PhD Resveratrol supplementation may reduce chronic pain in age-related osteoarthritis and improve menopause-related quality of life in postmenopausal women. These improvements can be sustained for at least 12 months and appear to be partly mediated by enhancement of circulatory function.

50

Comparison of performance and health indicators between perimenopausal and postmenopausal obese women: the effect of high-intensity interval training (HIIT) Georges Jabbour, PhD, and Horia D. Iancu, PhD

A six-week high intensity interval training intervention improved many health and performance parameters and reduced the effects of menopause and age.

58

Relationship between the use of Chinese herbal medicines and Sjögren syndrome risk among women with menopause: a retrospective cohort study

Yu-Jung Chung, MD, Chang-Kuo Wei, MD, Hanoch Livneh, PhD, Ning-Sheng Lai, MD, PhD, Ming-Chi Lu, MD, PhD, Hou-Hsun Liao, MD, and Tzung-Yi Tsai, PhD A statistically significant association was found between Chinese herbal medicines (CHMs) use and lower risk of Sjögren's syndrome (SS) onset in menopausal women, suggesting that CHMs could possibly be integrated into conventional therapy to reduce subsequent SS risk for menopausal women.

65

Assessment of menopausal symptoms and quality of life in women with premature ovarian failure after hematopoietic stem-cell transplantation for hematologic diseases

Huina Su, MD, Huiling Li, MD, Xin Yang, MD, Chaohua Wang, MD, and Yang Zhao, MD Compared with natural menopausal women with the same number of years since menopause, the Menopause Rating Scale (MRS) and Kupperman Index scores of women with premature ovarian failure who underwent hematopoietic stem cell transplantation showed that this group had milder symptoms. The MRS may be a better alternative to reflect the severity of menopausal symptoms.

SDC

70

Onset of the climacteric phase by the mid-forties associated with impaired insulin sensitivity: a birth cohort study

Susanna M. Savukoski, MD, Eila T. J. Suvanto, MD, Juha P. Auvinen, MD, Paula R. O. Pesonen, MSc, Sirkka M. Keinänen-Kiukaanniemi, MD, Katri S. Puukka, PhD, Tapani Ebeling, MD, and Maarit J. Niinimäki, MD

Glucose metabolism was compared between climacteric and preclimacteric women at age 46. Earlier onset of the climacteric transition was found to be associated with impaired insulin sensitivity.

SDC

80

Acupuncture ameliorated vasomotor symptoms during menopausal transition: single-blind, placebo-controlled, randomized trial to test treatment efficacy

Jose M. Soares-Jr, MD, PhD, Alexandre C. Branco-de-Luca, MD, PhD, Angela M. da Fonseca, MD, PhD, Ceci M. Carvalho-Lopes, MD, PhD, Eduardo C. Arruda-Veiga, PhD, Cristiane L. Roa, MD, Vicente R. Bagnoli, MD, PhD, and Edmund C. Baracat, MD, PhD

Acupuncture treatment may mitigate hot flashes and other climacteric symptoms during the menopausal transition.

Brief Report



86

Behavioral and psychological health inequities in income disparate perimenopausal women: a brief report

Kirsten A. Dickins, PhD, AM, MSN, FNP-C, and Sara E. Looby, PhD, ANP-BC, FAAN Awareness of how the social determinants of health impact outcomes among vulnerable perimenopausal women is critical to developing equitable aging opportunities, including customized preventive health screenings and interventions that engage income disparate perimenopausal women.

Clinical Corner

NAMS Practice Pearl

93

Fibromyalgia screening in patients with unexplained chronic fatigue

Christopher A. Aakre, MD, MSc

Perimenopausal and postmenopausal women often complain of symptoms of fatigue and generalized aches and pains. Even though fibromyalgia is more prevalent in midlife women, not all women presenting with aches and pain and disrupted sleep meet diagnostic criteria for fibromyalgia. This Practice Pearl addresses the distinction between chronic fatigue syndrome and fibromyalgia and the management of fibromyalgia.

Review Articles



96

Migraine and menopause - a narrative review

Carolyn Bernstein, MD, and Mary A. O'Neal, MD

This is a narrative review of neurologic considerations for women with migraine in perimenopause and after the menopause transition. The review covers prevalence, stroke risk and best practice for migraine management.

102

The effect of pathophysiological changes in the vaginal milieu on the signs and symptoms of genitourinary syndrome of menopause (GSM)

Wenhui Qi, MD, Huiyang Li, MD, Chen Wang, MD, Huanrong Li, MD, Aiping Fan, MD, PhD, Cha Han, MD, PhD, and Fengxia Xue, MD, PhD

In women with genitourinary symptoms of menopause (GSM), low hormone states can result in pathophysiological changes in the vaginal milieu, including the vaginal microbiome and the mucosal immunity. Hormone-associated disruption of the balance of the indigenous microbiota and the dysregulation of these immune responses are the pathophysiological basis of GSM symptoms.

Wolters Kluwer Health, Inc., and The North American Menopause Society cannot be held responsible for errors or for any consequences arising from the use of the information contained in this journal. All advertising material published in this journal is expected to conform to regulatory and medical standards. The appearance of advertising in this publication does not constitute a guarantee or endorsement by The North American Menopause Society or Wolters Kluwer Health, Inc., of the quality or value of such a product or service or any claims made by its marketer.

Permissions and photocopying: For permission and/or rights to use content for which the copyright holder is Wolters Kluwer or the society we have partnered with the Copyright Clearance Center to provide permissions for our products through their RightsLink service, please go to the journal's website and after clicking on the relevant article, click on the "Get Content & Permissions" link under the "Article Tools" box that appears on the right side of the page. For questions about the Rightslink service, e-mail customercare@copyright.com or call 877-622-5543 (U.S. Only) or 978-777-9929. Permissions FAQs and information on author's permission requests are available at https://shop.lww.com/journal-permission. For additional permission inquiries, please contact Permissions@LWW.com.

For translation rights requests, contact TranslationRights@wolterskluwer.com. For license to republish and distribute requests, contact HealthLicensing@ wolterskluwer.com. For special projects and reprints (U.S./Canada), contact Alan Moore at Alan.Moore@wolterskluwer.com or reprintsolutions@wolterskluwer.com. For special projects and reprints (non-U.S./Canada), contact Avia Potashnik at Avia.Potashnik@wolterskluwer.com or International-Reprints@wolterskluwer.com.

Menopause: The Journal of The North American Menopause Society is a registered trademark of The North American Menopause Society.

Menopause: The Journal of The North American Menopause Society (ISSN 1072-3714) is published monthly online-only by Wolters Kluwer Health, Inc. **Annual subscription rate:** \$641.

Copyright © 2021 by The North American Menopause Society. All rights reserved.